
AtriCure (ATRC) Stock Forecast & Price Target
AtriCure (ATRC) Analyst Ratings
Bulls say
AtriCure is well positioned to continue its double-digit sales growth driven by its innovative products in the fast-growing areas of cardiac ablation and LAA management. The company demonstrated strong sales and margin expansion in the 4Q25, and its earnings guidance for the upcoming year exceeds market expectations. Furthermore, AtriCure's potential for TAM expansion through clinical trials and adoption of its products as quality metrics in cardiac surgery adds to its long-term growth potential.
Bears say
AtriCure is facing competition in the LAAC market, particularly from Edwards Lifesciences, and while they have a strong position in the market due to their innovative product and proven efficacy and safety, the introduction of a competitor poses a potential risk to their market share and revenue growth. Additionally, slower than expected margin improvement and EBITDA growth, as well as weaker free cash flow, may further impact the company's financial performance. Despite these risks, we expect AtriCure to sustain at least low-teens overall revenue growth and reiterate our Buy rating.
This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.
AtriCure (ATRC) Analyst Forecast & Price Prediction
Start investing in AtriCure (ATRC)
Order type
Buy in
Order amount
Est. shares
0 shares